Is Re­gen­eron los­ing its R&D mys­tique? An­a­lyst dis­counts big biotech’s run­ner-up de­vel­op­ment strat­e­gy in an ...

6 years ago
R&D

Start­up EPM launch­es, high off cannabi­noid acid in­no­va­tion

6 years ago
Startups

Ex-Retrophin BD chief flips his rare dis­ease start­up on­to Nas­daq via re­verse merg­er with Pro­teon

6 years ago
Deals

Lund­beck’s Deb­o­rah Dun­sire didn’t just want an ex-US deal for Alder’s mi­graine drug. She want­ed the whole world

6 years ago
Deals

GW Phar­ma's cannabis-de­rived epilep­sy med­i­cine makes the cut in the Eu­ro­pean Union

6 years ago
FDA+

Servi­er be­gins manslaugh­ter tri­al over weight loss drug

6 years ago
Pharma

Once tout­ed as Lyri­ca ri­val for di­a­bet­ic nerve pain, Ko­re­an biotech's plas­mid prod­uct im­plodes in PhI­II

6 years ago
R&D

As­traZeneca vet heads to UK biotech as the new CSO; Mallinck­rodt touts pos­i­tive PhI­II da­ta

6 years ago
News Briefing

FDA puts the brakes on a rare dis­ease biotech’s PhI­II as reg­u­la­tors wait for an up­date — shares crum­ble

6 years ago
R&D
FDA+

Deep­en­ing US foot­print, As­traZeneca-part­nered French biotech In­nate shoots for $100M IPO

6 years ago
Financing

Akcea’s top 3 C-suite ex­ecs are chopped out as Io­n­is sends in an in­ter­im quar­ter­back from their bench

6 years ago
R&D

Amid Wood­ford de­ba­cle, Im­muno­core cuts val­u­a­tion as it se­cures $74M from Gen­er­al At­lantic — re­port

6 years ago
Financing

New Flag­ship biotech wants to un­leash your genome

6 years ago
Startups

A long-suf­fer­ing Clo­vis makes a leap in­to ra­dio­phar­ma­ceu­ti­cals, pay­ing $12M in cash to beef up the pipeline

6 years ago
Deals

Here comes the oral GLP-1 drug for di­a­betes — and No­vo Nordisk wants to price Ry­bel­sus 'at a sim­i­lar lev­el as ...

6 years ago
R&D
Pharma

Astel­las/Fi­bro­Gen's ane­mia drug for CKD pa­tients ap­proved in Japan; Re­searchers pro­pose com­bo to stay ahead of KRAS ...

6 years ago
News Briefing

Astel­las' AML drug wins over CHMP — strength­en­ing lead on Dai­ichi Sankyo

6 years ago
Pharma

In­trex­on unit push­es back against claims its GM mos­qui­toes are mak­ing dis­ease-friend­ly mu­tants

6 years ago
R&D
FDA+

Chris Roberts jumps back in­to biotech with CSO gig at Black Di­a­mond; Trou­bled Five Prime ap­points in­ter­im CEO

6 years ago
Peer Review

Pur­due threat­ens to walk away from set­tle­ment, asks to pay em­ploy­ees mil­lions in bonus­es

6 years ago
Pharma

Boehringer In­gel­heim en­lists an­oth­er vir­tu­al biotech part­ner for its for­ay in­to reti­nal dis­eases

6 years ago
Deals

Genen­tech sub­mits a big plan to ex­pand its South San Fran­cis­co foot­print

6 years ago
R&D
Pharma

As Nas­daq en­rolls the fi­nal batch of 2019 IPOs, how have the num­bers com­pared to past years?

6 years ago
Financing

Em­maus re­scinds EU mar­ket­ing ap­pli­ca­tion, fol­low­ing neg­a­tive re­view

6 years ago
Pharma
FDA+
First page Previous page 898899900901902903904 Next page Last page
A service from the Financial Times